Skip to main content
Premium Trial:

Request an Annual Quote

Biomedino Sues Waters, GE Healthcare, Agilent Over Drug Immunoassay Technology

NEW YORK, Jan. 13 (GenomeWeb News) - Seattle-based Biomedino has sued Waters, GE Healthcare, and Agilent Technologies for allegedly infringing its immunoassay technology for measuring psychoactive drugs, GenomeWeb News has learned.


Biomedino filed suit on Jan. 7 with the US District Court for the Western District of Washington, Seattledivision. The company claims that Waters, GE Healthcare, and Agilent infringe its USpatent No. 6,602,502, entitled "Methods and devices for removing species."


The patent, granted to Meir Strahilevitz, the sole inventor, in August 2003 and licensed to Biomedino, covers immunoassays of psychoactive drugs and treatment methods, based on the antigenic properties of protein conjugates of these drugs.


Biomedino said in its complaint that several chromatography-based separations systems made by the three plaintiffs infringe its patents. The company is seeking damages from all three "which in no event can be less than a reasonable royalty."


An Agilent spokesperson said the company has not yet been served with the suit. Officials from GE Healthcare and Waters did not immediately return a telephone call seeking comment.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.